A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

Table 8 Incosistency tests for non-hematological toxicities of different CCRT regimens in the treatment of LA-NSCLC

Pairwise comparisons	Direct OR values			Indirect OR values			P values
Pairwise comparisons	Nausea/vomiting	Esophagitis	Pneumonitis	Nausea/vomiting	Esophagitis	Pneumonitis	Nausea/vomiting	Esophagitis	Pneumonitis
A VS. B	-0.52	-0.18	-0.05	-1.93	-0.40	1.25	0.430	0.839	0.432
A VS. D	-0.24	0.01	-0.20	0.65	-0.91	0.46	0.977	0.970	0.980
A VS. E	1.02	-0.10	2.58	2.44	0.12	1.27	0.430	0.839	0.431
B VS. G	2.43	-0.65	0.92	2.22	-0.76	1.11	0.800	0.900	0.817
B VS. N	0.34	-1.36	0.19	0.24	-1.41	0.29	0.906	0.964	0.905
C VS. D	NR	-0.35	-1.56	NR	0.08	0.07	NR	0.996	0.985
C VS. F	NR	-0.27	-0.11	NR	-0.99	-2.84	NR	0.997	0.989
D VS. H	-1.06	2.09	1.20	-0.11	1.04	2.22	0.976	0.969	0.971
E VS. G	-0.52	-0.96	-0.41	0.90	-0.73	-1.72	0.430	0.839	0.432
F VS. H	-0.63	0.12	0.89	-1.62	1.17	-0.22	0.976	0.970	0.970
F VS. I	-0.20	-0.73	-1.42	0.89	-1.69	-0.09	0.976	0.974	0.967
G VS. N	-2.09	-0.71	-0.73	-1.99	-0.66	-0.84	0.906	0.964	0.905
I VS. K	-0.28	-0.52	-0.12	0.93	-1.33	1.35	0.977	0.980	0.966
K VS. L	0.91	1.41	NR	3.22	-0.03	NR	0.991	0.994	NR
K VS. O	NR	NR	1.10	NR	NR	3.95	NR	NR	0.989
K VS. Q	2.34	0.72	0.88	4.65	-0.72	3.73	0.991	0.994	0.989
K VS. R	NR	0.17	0.39	NR	-1.27	3.24	NR	0.994	0.989

A, CCRT (cisplatin + etoposide); B, CCRT (carboplatin + paclitaxel); C, CCRT (pemetrexed + carboplatin); CCRT Concurrent chemoradiotherapy; D, CCRT (pemetrexed + cisplatin); E, CCRT (docetaxel + cisplatin); F, CCRT (S-1 + cisplatin); G, CCRT (mitomycin + vindesine + cisplatin); H, CCRT (cisplatin + vinorelbine); I, CCRT (cisplatin); K, RT; L, CCRT (5-FU); LA-NSCLC Locally advanced non-small cell lung cancer; N, CCRT (irinotecan + carboplatin); NR Not report; O, CCRT (nedaplatin); OR Odds radios; Q, CCRT (paclitaxel); R, CCRT (carboplatin)

ISSN: 1471-2407